Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study.

Arthritis Research & Therapy
Athanasios N GeorgiadisAlexandros A Drosos

Abstract

We investigated lipid profiles and lipoprotein modification after immuno-intervention in patients with early rheumatoid arthritis (ERA). Fifty-eight patients with ERA who met the American College of Rheumatology (ACR) criteria were included in the study. These patients had disease durations of less than one year and had not had prior treatment for it. Smokers or patients suffering from diabetes mellitus, hypothyroidism, liver or kidney disease, Cushing's syndrome, obesity, familiar dyslipidemia and those receiving medications affecting lipid metabolism were excluded from the study. Sixty-three healthy volunteers (controls) were also included. Patients were treated with methotrexate and prednisone. Lipid profiles, disease activity for the 28 joint indices score (DAS-28) as well as ACR 50% response criteria were determined for all patients. The mean DAS-28 at disease onset was 5.8 +/- 0.9. After a year of therapy, 53 (91.3%) patients achieved the ACR 20% response criteria, while 45 (77.6%) attained the ACR 50% criteria. In addition, a significant decrease in the DAS-28, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were observed. ERA patients exhibited higher serum levels of total cholesterol (TC), low-density...Continue Reading

References

Jan 1, 1975·Scandinavian Journal of Rheumatology·H A IsomäkiK Koota
Aug 5, 1988·JAMA : the Journal of the American Medical Association·V ManninenP Koskinen
Apr 1, 1987·Arthritis and Rheumatism·R S Pinals
Jun 1, 1986·Arthritis and Rheumatism·D M MitchellJ F Fries
Nov 28, 1986·JAMA : the Journal of the American Medical Association·W P CastelliW B Kannel
Aug 1, 1985·British Journal of Rheumatology·M LorberJ G Brook
Jun 15, 1985·British Medical Journal·O MutruK Koota
Jun 1, 1997·Annals of the Rheumatic Diseases·R D Situnayake, G Kitas
Jun 1, 1997·Annals of the Rheumatic Diseases·R MunroH A Capell
Nov 26, 1999·Circulation·V Pasceri, E T Yeh
Feb 15, 2002·Current Opinion in Rheumatology·Nicola Goodson
Apr 16, 2002·Arthritis and Rheumatism·S Van DoornumI P Wicks
Oct 16, 2002·Annals of the Rheumatic Diseases·E M Gravallese
Jan 16, 2003·Arthritis and Rheumatism·Sherine E GabrielEric L Matteson
Feb 8, 2003·Atherosclerosis. Supplements·P J Barter

❮ Previous
Next ❯

Citations

Oct 27, 2009·Annals of the Rheumatic Diseases·Elena MyasoedovaSherine E Gabriel
Jun 1, 2010·Therapeutic Advances in Musculoskeletal Disease·Awal Al Husain, Ian N Bruce
Mar 8, 2008·Arthritis Research & Therapy·Antonio NaranjoUNKNOWN QUEST-RA Group
Jun 19, 2009·Journal of Lipid Research·F ApostolouE N Liberopoulos
May 5, 2010·Clinical Medicine : Journal of the Royal College of Physicians of London·John R Kirwan
Aug 6, 2014·Nature Reviews. Rheumatology·György KerekesZoltán Szekanecz
Dec 8, 2010·Rheumatology International·Natalí Serra-Bonett, Martín A Rodríguez
Sep 1, 2009·Expert Opinion on Investigational Drugs·Robert J MootsJohn D Isaacs
Mar 7, 2008·Expert Opinion on Emerging Drugs·Paraskevi V Voulgari
Sep 26, 2007·Annals of the New York Academy of Sciences·Roberto GerliYehuda Shoenfeld
May 19, 2010·Scandinavian Journal of Rheumatology·N TsifetakiA A Drosos
Apr 1, 2015·Nature Reviews. Rheumatology·Sarah Skeoch, Ian N Bruce
Jun 15, 2010·Autoimmunity Reviews·Elena BartoloniRoberto Gerli
Apr 9, 2008·Seminars in Arthritis and Rheumatism·Adriana Rojas-VillarragaJuan-Manuel Anaya
Oct 30, 2016·Journal of Proteome Research·Filippos MichopoulosGeorgios A Theodoridis
Dec 30, 2014·International Journal of Rheumatic Diseases·Vachana Murunikkara, Mahaboob K Rasool
Jan 1, 2008·Archives of Physical Medicine and Rehabilitation·Huifang LiangCarol L Braunschweig
Feb 24, 2018·Frontiers in Medicine·Stergios SoulaidopoulosGeorge D Kitas
Aug 2, 2013·Therapeutic Advances in Musculoskeletal Disease·Inge A M van den OeverMichael T Nurmohamed
May 16, 2018·European Journal of Preventive Cardiology·José TuñónUNKNOWN ESC Working Group on Atherosclerosis and Vascular Biology
May 31, 2018·Current Rheumatology Reports·Eun Ha KangSeoyoung C Kim
Nov 4, 2015·Clinical Rheumatology·Sara Manrique-ArijaAntonio Fernández-Nebro

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.